DEVELOPMENT AND COMMERCIALIZATION AGREEMENTDevelopment and Commercialization Agreement • February 11th, 2011 • Cephalon Inc • Pharmaceutical preparations • New York
THIS DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (“Agreement”) dated as of December 7, 2010 (“Effective Date”), is entered into by and between Angioblast Systems Inc., a Delaware corporation having its principal place of business at 275 Madison Ave., 4th floor, New York, New York 10016 (“Angioblast”) and Cephalon, Inc., a Delaware corporation having its principal place of business at 41 Moores Road, Frazer, Pennsylvania 19355 (“Cephalon”).
SETTLEMENT AND LICENSE AGREEMENTSettlement and License Agreement • February 11th, 2011 • Cephalon Inc • Pharmaceutical preparations • Delaware
This Settlement and License Agreement (the “Agreement”) is entered into this 7th day of October, 2010 (the “Agreement Date”), by and between Anesta AG and Eurand, Inc., each on their own behalf and on behalf of their Affiliates, and Impax Laboratories, Inc., on its own behalf and on behalf of its Affiliates.
STOCK PURCHASE AGREEMENTStock Purchase Agreement • February 11th, 2011 • Cephalon Inc • Pharmaceutical preparations • Delaware
This STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of December 7, 2010 by and among Angioblast Systems, Inc., a Delaware corporation (the “Company”), the individuals and entities listed on Exhibit A hereto (the “Sellers,” and each a “Seller”), the individuals and entities listed on Exhibit B hereto (the “Non-Selling Holders”) and Cephalon International Holdings, Inc. (the “Purchaser”).
